382 related articles for article (PubMed ID: 33921638)
1. The Targeting of MRE11 or RAD51 Sensitizes Colorectal Cancer Stem Cells to CHK1 Inhibition.
Mattiello L; Soliman Abdel Rehim S; Musella M; Sistigu A; Guarracino A; Vitale S; Corradi F; Galassi C; Sperati F; Manic G; De Maria R; Vitale I
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33921638
[TBL] [Abstract][Full Text] [Related]
2. Control of replication stress and mitosis in colorectal cancer stem cells through the interplay of PARP1, MRE11 and RAD51.
Manic G; Musella M; Corradi F; Sistigu A; Vitale S; Soliman Abdel Rehim S; Mattiello L; Malacaria E; Galassi C; Signore M; Pallocca M; Scalera S; Goeman F; De Nicola F; Guarracino A; Pennisi R; Antonangeli F; Sperati F; Baiocchi M; Biffoni M; Fanciulli M; Maugeri-Saccà M; Franchitto A; Pichierri P; De Maria R; Vitale I
Cell Death Differ; 2021 Jul; 28(7):2060-2082. PubMed ID: 33531658
[TBL] [Abstract][Full Text] [Related]
3. A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation.
Xiao Z; Xue J; Sowin TJ; Rosenberg SH; Zhang H
Oncogene; 2005 Feb; 24(8):1403-11. PubMed ID: 15608676
[TBL] [Abstract][Full Text] [Related]
4. A pan-cancer transcriptome analysis identifies replication fork and innate immunity genes as modifiers of response to the CHK1 inhibitor prexasertib.
Blosser WD; Dempsey JA; McNulty AM; Rao X; Ebert PJ; Lowery CD; Iversen PW; Webster YW; Donoho GP; Gong X; Merzoug FF; Buchanan S; Boehnke K; Yu C; You XT; Beckmann RP; Wu W; McNeely SC; Lin AB; Martinez R
Oncotarget; 2020 Jan; 11(3):216-236. PubMed ID: 32076484
[TBL] [Abstract][Full Text] [Related]
5. CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells.
Manic G; Signore M; Sistigu A; Russo G; Corradi F; Siteni S; Musella M; Vitale S; De Angelis ML; Pallocca M; Amoreo CA; Sperati F; Di Franco S; Barresi S; Policicchio E; De Luca G; De Nicola F; Mottolese M; Zeuner A; Fanciulli M; Stassi G; Maugeri-Saccà M; Baiocchi M; Tartaglia M; Vitale I; De Maria R
Gut; 2018 May; 67(5):903-917. PubMed ID: 28389531
[TBL] [Abstract][Full Text] [Related]
6. Thymineless Death by the Fluoropyrimidine Polymer F10 Involves Replication Fork Collapse and Is Enhanced by Chk1 Inhibition.
Mani C; Pai S; Papke CM; Palle K; Gmeiner WH
Neoplasia; 2018 Dec; 20(12):1236-1245. PubMed ID: 30439567
[TBL] [Abstract][Full Text] [Related]
7. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K
Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187
[TBL] [Abstract][Full Text] [Related]
8. The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human Neuroblastoma.
Lowery CD; VanWye AB; Dowless M; Blosser W; Falcon BL; Stewart J; Stephens J; Beckmann RP; Bence Lin A; Stancato LF
Clin Cancer Res; 2017 Aug; 23(15):4354-4363. PubMed ID: 28270495
[No Abstract] [Full Text] [Related]
9. Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.
Massey AJ
Cancer Lett; 2016 Dec; 383(1):41-52. PubMed ID: 27693461
[TBL] [Abstract][Full Text] [Related]
10. CNS penetration and pharmacodynamics of the CHK1 inhibitor prexasertib in a mouse Group 3 medulloblastoma model.
Campagne O; Davis A; Maharaj AR; Zhong B; Stripay J; Farmer D; Roussel MF; Stewart CF
Eur J Pharm Sci; 2020 Jan; 142():105106. PubMed ID: 31669383
[TBL] [Abstract][Full Text] [Related]
11. Replication stress response in cancer stem cells as a target for chemotherapy.
Manic G; Sistigu A; Corradi F; Musella M; De Maria R; Vitale I
Semin Cancer Biol; 2018 Dec; 53():31-41. PubMed ID: 30081229
[TBL] [Abstract][Full Text] [Related]
12. Prexasertib, a checkpoint kinase inhibitor: from preclinical data to clinical development.
Angius G; Tomao S; Stati V; Vici P; Bianco V; Tomao F
Cancer Chemother Pharmacol; 2020 Jan; 85(1):9-20. PubMed ID: 31512029
[TBL] [Abstract][Full Text] [Related]
13. CHK1/2 Inhibitor Prexasertib Suppresses NOTCH Signaling and Enhances Cytotoxicity of Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma.
Zeng L; Nikolaev A; Xing C; Della Manna DL; Yang ES
Mol Cancer Ther; 2020 Jun; 19(6):1279-1288. PubMed ID: 32371584
[TBL] [Abstract][Full Text] [Related]
14. UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response.
Signore M; Buccarelli M; Pilozzi E; De Luca G; Cappellari M; Fanciulli M; Goeman F; Melucci E; Biffoni M; Ricci-Vitiani L
Oncotarget; 2016 Jul; 7(28):44113-44128. PubMed ID: 27286453
[TBL] [Abstract][Full Text] [Related]
15. Novel indication for cancer therapy: Chk1 inhibition sensitizes tumor cells to antimitotics.
Xiao Z; Xue J; Semizarov D; Sowin TJ; Rosenberg SH; Zhang H
Int J Cancer; 2005 Jul; 115(4):528-38. PubMed ID: 15688426
[TBL] [Abstract][Full Text] [Related]
16. ATR/CHK1 inhibitors and cancer therapy.
Qiu Z; Oleinick NL; Zhang J
Radiother Oncol; 2018 Mar; 126(3):450-464. PubMed ID: 29054375
[TBL] [Abstract][Full Text] [Related]
17. Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases
Brill E; Yokoyama T; Nair J; Yu M; Ahn YR; Lee JM
Oncotarget; 2017 Dec; 8(67):111026-111040. PubMed ID: 29340034
[TBL] [Abstract][Full Text] [Related]
18. Synthetic Lethality with Trifluridine/Tipiracil and Checkpoint Kinase 1 Inhibitor for Esophageal Squamous Cell Carcinoma.
Ohashi S; Kikuchi O; Nakai Y; Ida T; Saito T; Kondo Y; Yamamoto Y; Mitani Y; Nguyen Vu TH; Fukuyama K; Tsukihara H; Suzuki N; Muto M
Mol Cancer Ther; 2020 Jun; 19(6):1363-1372. PubMed ID: 32371587
[TBL] [Abstract][Full Text] [Related]
19. Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models.
Lowery CD; Dowless M; Renschler M; Blosser W; VanWye AB; Stephens JR; Iversen PW; Lin AB; Beckmann RP; Krytska K; Cole KA; Maris JM; Hawkins DS; Rubin BP; Kurmasheva RT; Houghton PJ; Gorlick R; Kolb EA; Kang MH; Reynolds CP; Erickson SW; Teicher BA; Smith MA; Stancato LF
Clin Cancer Res; 2019 Apr; 25(7):2278-2289. PubMed ID: 30563935
[TBL] [Abstract][Full Text] [Related]
20. Cyclin B1 is an efficacy-predicting biomarker for Chk1 inhibitors.
Xiao Z; Xue J; Gu WZ; Bui M; Li G; Tao ZF; Lin NH; Sowin TJ; Zhang H
Biomarkers; 2008 Sep; 13(6):579-96. PubMed ID: 18671143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
